GlobeNewswire

JBS USA, LLC : JBS Names Former U.S. Department of Agriculture Deputy Under Secretary for Food Safety as Global Head of Food Safety and Quality Assurance

Dela

GREELEY, Colo., Aug. 03, 2017 (GLOBE NEWSWIRE) -- As part of the company's effort to serve as the worldwide leader in high-quality, innovative protein and value-added food products, JBS today announced the appointment of Alfred "Al" Almanza to the role of Global Head of Food Safety and Quality Assurance. 

Almanza will join the JBS Global leadership team, reporting directly to JBS Global President of Operations, Gilberto Tomazoni. Based in Greeley, Colo., he will lead the company's global food safety efforts, ensuring that JBS operations around the world implement the highest food safety, quality control and risk management systems, while maintaining and expanding access to global export markets. JBS is the worldwide leader in protein exports, serving more than 300,000 customers in more than 150 nations. 

Prior to joining JBS, Almanza spent nearly 40 years with the U.S. Department of Agriculture, Food Safety and Inspection Service (USDA, FSIS). He began his career with USDA as a food safety inspector in a small plant in Dalhart, Texas, eventually rising from this entry-level position to serve as Deputy Under Secretary for Food Safety under Secretary of Agriculture Thomas J. Vilsack, from September 2014 to December 2016. For the past 10 years, he has served as the Administrator of FSIS, leading USDA's science-based food safety modernization efforts, regulatory strategies and public health efforts to prevent foodborne illness.

"We are delighted to bring Al's expertise and passion for food safety, quality and public health to the JBS team," Tomazoni said. "During his long and storied career at FSIS, Al earned the respect and admiration of his peers for his team-based management approach and his willingness to partner with both industry and public health organizations to ensure the provision of safe, quality food to consumers. JBS is privileged to have someone of Al's caliber join our company."

Almanza is globally recognized as an expert on food safety, risk management, the development of modern inspection systems, and international sanitary standards that govern market access for meat and poultry products. During his time at FSIS, he held several leadership positions, including Labor Management specialist, District Manager of the Agency's Dallas District Office, and ultimately Administrator of FSIS, where he led a team of more than 7,000 FSIS field employees.

"I am excited to start this new chapter of my career as a part of the JBS Global Team," Almanza said. "It was an honor to serve the public as a member of the USDA team and help uphold its mission to protect public health for nearly four decades. I now join a team that shares my commitment to food safety and feeding the world in a safe, sustainable way. I look forward to helping JBS maintain the highest food safety levels in the industry, and putting in place best-in-class benchmarks and safeguards to ensure that our products continue to exceed all industry standards."

ABOUT JBS
JBS is the leading animal protein producer in the world and the second-largest food company in the world, with production platforms in South America, North America, Europe and Oceania. Founded in 1953, JBS has more than 235,000 team members worldwide, more than 300 production units, export customers in more than 150 countries, and annual revenues of more than $50 billion. JBS processes, prepares, packages and delivers fresh, further-processed and value-added beef, pork, lamb and poultry products for sale to more than 300,000 customers in more than 150 countries on six continents.

Contact:
Cameron Bruett, JBS Corporate Affairs
Cameron.bruett@jbssa.com
970-506-7801




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: JBS USA, LLC via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum